The Ademi Firm is investigating Paragon 28 (NYSE: FNA) for possible breaches of fiduciary duty and other violations of law in its transaction with Zimmer Biomet. Click here to learn how to join our ...
Paragon 28, Inc. (NYSE: FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the expiration of the waiting ...
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Paragon 28, Inc. (NYSE: FNA) to Zimmer ...
NEW YORK, NY / ACCESS Newswire / March 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
Paragon 28, Inc. (NYSE:FNA – Get Free Report) was the recipient of a significant drop in short interest in February. As of February 15th, there was short interest totalling 1,800,000 shares ...
Paragon 28, Inc. (NYSE:FNA – Get Free Report) has been given a consensus rating of “Hold” by the six research firms that are presently covering the firm, MarketBeat.com reports.
ENGLEWOOD, Colo., March 07, 2025--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to ...
The Ademi Firm is investigating Paragon 28 (NYSE: FNA) for possible breaches of fiduciary duty and other violations of law in its transaction with Zimmer Biomet. Click here to learn how to join ...
Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the expiration of ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback